Santen Buys Asia, Europe Rights To Merck's Eye Drugs For $600 Million
This article was originally published in PharmAsia News
Santen Pharmaceutical has licensed eye drugs from Merck for $600 million upfront, plus milestone payments and royalties, to market them in the Asia Pacific region and in Europe.
You may also be interested in...
Cancer-focused biotech obtains preclinical program aimed at leukemia subset involving chromosomal rearrangements. Merck acquires an interest in KalVista and rights to its diabetic macular edema candidate, while Arcturus partners with Janssen in hepatitis B.
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.